Katarina Hedbeck 0:05
Who here likes to be stuck by a needle? No, I did not think so. But sometimes it's needed, isn't it? You're at a hospital and you need fluid. It's the most common invasive procedure 90% of hospital patients admitted to hospital will receive IV 16 billion IV lines and one and a half billion catheters are used every year. There is a problem though there are forces on the tube. When the force is strong enough, the catheter gets ripped out. This happens in 10% of the cases. That's quite a lot. There are disastrous consequences safety issue for both the patient as well as the healthcare personnel sustainability as well as financial. From the patient's point of view, there will be an injury on the hand, there is risk for infection and even death. If the patient is infectious or has a blood borne disease, or if it's chemo or any toxic medicine in the IV bag, they will risk for toxic exposure on the healthcare personnel. And after such an accident, everything needs to be thrown away the IV bag everything in it. This adds up to 23,000 ton of unnecessary plastic waste. And I say unnecessary. Because there is a solution there is linkers. So in our case, when there is a force on the IV line, our connector splits into two parts. Double voles keep blood and medicine from spilling, you can use the protocols at the hospital to clean them to reconnect and rapidly reinstate therapy. We have developed this as a platform technology for tubes going in and out of the body. The examples here are IV therapy, I will come to in customer drainage in a bit. So it's a platform technology with a huge potential. There are a state of the market today is to secure it stronger and stronger. There are two competitors that are addressing it like we are doing with a weak link. The differentiation here is that are three connectable thus saving more time and money for the hospitals. There are two key drivers for relink for link as relink is the European name link us, the US the scale 16 billion IV lines and a chronic shortage and it's a chronic shortage at scale. Here I write chronic shortage of nursing staff, but it could have as just as well have been medicine or specific medicine because you can aim for these parts as well as hospital beds are first bass patent is approved in 16 countries and then we have four additional patents approved. We have the CE mark approval approval from a regular point of view for an approximate Vantage when we get there. We expect the FDA approval within one month. And we are ISO 13 485 certified. I'm Katerina, CEO and co founder and I met my co founders through clinical Innovation Fellowship where we followed the Stanford be a design process. So we we found the need for safer infusion. My background is engineering plus an MBA I work my entire life we product and business development. My co founder Rebecca has a PhD in engineering sciences, and Christopher's medical doctor anesthesiologist. Since last year, Andrea San Antonio joined our board. So that's totally amazing. It's a groundbreaking thing. We're very grateful for them. We've also hand picked an amazing team. We're based in Stockholm. Dara works out of Ireland. But apart from that we're all Swedish based company. We have concluded our first clinical trial with a 73% success rate in dislodgement, the Professor and Associate professor wrote an article in we submitted abstracts it was picked up from the Cova. We will present their API is coming next we will we don't know if the results yet but we hope to present there as well. We have an addition five clinical trials ongoing thanks to the European Innovation Council who has sponsored us with most of the clinical trials, they are also looking very, very good. So the value proposition is safer and efficient IV therapy 73% reduction in IV dislodgement 90%, less time to restart and reduction of 89% in restart cost. And this is something that happens over and over again. So the impact that we can do here is amazing. The value for the sales distributors that we want to partner up with. They also have it it's a spillover effect if you kept it together with other parts so you can activate a higher price realization higher volumes and new markets. We have financial modeling When we put in actual numbers, and one example for one distributor was that, over a period of time, they could have four times the growth, their organic growth in this example is 20% increase in their market, but by adding it to a kit and having a little bit of price Delta increase, as well as little bit more market share and opening up new business areas, you can have five times the the reps, so no wonder that we are already talking to quite a few of those and have come to four stages with agreements a letter of intent, what we do need to do. Apart from those things, it's obviously getting the product more out to the hospital at the moment, we are in seven hospitals. And we have those advanced agreements, we working on the pricing great because we need to get the price down per piece, but we know exactly how much would the words, pay etcetera. And to get there, we need Of course money to scale. And also here we have a plan like three step plan on how to reduce it. So unlock scale, reduce the cost and trigger the demand. And by 2028, according to our predictions, our volume of 43 million relink sold, and that would give us 100 million euros, we need eight and a half to fully do the fully scaling and that would be investment in tools and machines commercial expansion as well as one new product development for a new platform. But we have a possibility to join a Bridge already now. Because there are two value enhancers that will happen very very shortly. So we will get the FDA and then we have initial sales for the second half of this year. So please join us in our rich round or contact us if we want to do the series A it within Yeah. So first step, bridge round, reduce manufacturing costs sequentially, step one, and then initial commercialization before going full on. Thank you
© 2024 Life Science Intelligence, Inc., All Rights Reserved.
